BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
Witjes
W P
WP
Department of Urology, University of Nijmegen, The Netherlands.
van der Meijden
P M
PM
Roos
E P
EP
Witjes
J A
JA
Steerenberg
P A
PA
Doesburg
W
W
Debruyne
F M
FM
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000628:therapy; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy; D011446:Prospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000628:therapy*
D001500:BCG Vaccine; D016685:Mitomycin